Early-stage venture capital firm Oxford Science Enterprises (OSE) has secured an additional £250m to fund deeptech, healthtech, and life science spinouts from the University of Oxford.
It provides initial funding, support, industry experts and startup infrastructure to companies based on work inside of the university.
Alexis Dormandy, CEO of Oxford Science Enterprises, said: “We are delighted to successfully complete this new fundraising. Attracting such high-quality new and existing global investors reflects their enthusiasm for the strength of Oxford’s science and our plans to drive positive impact from it.”
The injection of capital came from international investors, blue chips, sovereign wealth funds, family offices, pension funds and asset managers.
Founded in 2015, OSE has invested in more than 80 companies, producing two IPOs and five trade exits. Its latest raise brings its total funding to over £850m.
“Our companies are making remarkable breakthroughs from cancer, heart failure and infectious diseases, to climate change, food security and quantum computing,” added Dormandy.
“Over the next few years, we expect these companies will continue to make important progress; with our ongoing efforts, and the support of our shareholders, we look forward to helping them deliver impact and returns.”
That’s in addition to ORCA Computing, which recently received an order from the Ministry of Defence for one of its quantum computers.
OSE is not the only investor to work with the University of Oxford. Parkwalk Advisors, whose CEO and co-founder Moray Wright recently spoke to UKTN, helps it to manage its own funds.